The Binding Site

The Binding Site The Specialist Protein Company

Binding Site, Part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation. Binding Site provide diagnostic solutions that help doctors, clinicians and laboratory researchers across the globe diagnose and monitor blood cancers and immune system disorders. Founded by researchers at the University of Birmingham, Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers and clinicians for over 30 years. We are committed to working in collaboration with our partners and customers to lead the way in specialized medical diagnostics, ensuring we continue to make a difference together.

18/02/2026

Multiple Myeloma is a type of blood cancer that affects plasma cells, a component of our immune system. This condition leads to the accumulation of cancerous plasma cells in the bone marrow and monoclonal proteins in the blood.

As a result, the production of healthy blood cells is disrupted, leading to an array of complications. Early detection is crucial, and delays in diagnosis can lead to severe comorbidities and reduced survival rates.

Discover more about Multiple Myeloma and how primary care providers play a key role in its early detection 👉 http://spr.ly/6187hdPTz

16/02/2026

A dedicated analyser is the best solution for handling the complex assay protocols required for special protein assays.

Here is how a standalone solution for protein analysis, like the Optilite® Analyser, can help:

✅ Avoid manual dilutions, saving time and reducing analytical errors
✅ Eliminate the need to train staff on exceptions to standard automated procedures
✅ Optimize turnaround times for both special protein and clinical chemistry workflows
✅ Utilize integrated solutions such as peer-to-peer QC software

The Optilite® Analyser delivers an end-to-end solution with minimal bench space required, no extra plumbing, and is easy to implement and learn for your laboratory staff.

Learn more 👉 http://spr.ly/6187hTvLd

Multiple Myeloma often presents with symptoms such as general unwellness, fatigue, and persistent bone pain. These sympt...
13/02/2026

Multiple Myeloma often presents with symptoms such as general unwellness, fatigue, and persistent bone pain. These symptoms can overlap with those commonly experienced by the elderly population, who are at a higher risk of developing the disease.

This makes it challenging to recognize the disease. Primary care providers play a crucial part in identifying symptoms early and ordering the necessary tests to ensure a prompt diagnosis.

Download the “Multiple Myeloma: Signs and Symptoms” guidance to learn more 👉 http://spr.ly/6186hTxyY

12/02/2026

Monoclonal Gammopathy of Undetermined Significance (MGUS) is often encountered by primary care providers, but what is MGUS?

Discover why this condition, a precursor to multiple myeloma, is important and why patients require monitoring. Learn more about MGUS and its significance here 👉 http://spr.ly/6182hRMJ2

Multiple Myeloma is a type of blood cancer that affects plasma cells, a component of our immune system. This condition l...
09/02/2026

Multiple Myeloma is a type of blood cancer that affects plasma cells, a component of our immune system. This condition leads to the accumulation of cancerous plasma cells in the bone marrow and monoclonal proteins in the blood.

As a result, the production of healthy blood cells is disrupted, leading to an array of complications. Early detection is crucial, and delays in diagnosis can lead to severe comorbidities and reduced survival rates.

Discover more about Multiple Myeloma and how primary care providers play a key role in its early detection. http://spr.ly/6185hMwZ7

Monoclonal gammopathies, also called plasma cell dyscrasias, are conditions marked by the clonal expansion of plasma cel...
04/02/2026

Monoclonal gammopathies, also called plasma cell dyscrasias, are conditions marked by the clonal expansion of plasma cells and production of monoclonal proteins.

These disorders include malignant blood cancers like Multiple Myeloma and precursor conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM).

Understanding these conditions is crucial for early detection and appropriate patient management.

Learn more about these disorders 👉 http://spr.ly/6189hyk9b

The Optilite® Analyser is designed to meet the growing need for specialized protein testing, providing accurate results ...
02/02/2026

The Optilite® Analyser is designed to meet the growing need for specialized protein testing, providing accurate results that aid in early diagnosis and monitor patients through their journey.

Explore the benefits of implementing a dedicated protein analyser below.

Learn more 👉 http://spr.ly/6185hDezF

26/01/2026

Clinical diagnostic laboratories are facing immense pressure from rising workloads, increased administrative burdens, staff shortages, and the need to do more with less. While consolidating assays onto a single platform might seem beneficial, running special protein assays on clinical chemistry analysers can disrupt the streamlined and automated workflows you rely on.

Sonic HealthCare shared how the Optilite® Analyser has revolutionized their laboratory operations

Learn more 👉 http://spr.ly/6181h6Dgx

Some patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) develop renal disorders, known as "Monoclon...
26/01/2026

Some patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) develop renal disorders, known as "Monoclonal Gammopathies of Renal Significance" (MGRS).

Dive deeper into this topic and discover more about Monoclonal Gammopathies of Renal Significance in this white paper. Learn more 👉 http://spr.ly/6181h6Dk1

19/01/2026

In the fast-paced world of clinical diagnostics, laboratories are under unprecedented pressure with rising workloads and staffing challenges. The Optilite® Analyser delivers highly accurate protein testing, allowing clinicians to identify conditions sooner and monitor patients through their journey.

Watch the video to hear Astrid Coppens, CEO Sonic HealthCare Belgium, discuss how implementing the Optilite Analyser led to improvements in lab switching and doubled the reporting time.

Learn more 👉 http://spr.ly/6182CNtLp

15/01/2026

While Monoclonal Gammopathy of Undetermined Significance (MGUS) is often discussed in relation to its progression to multiple myeloma, it's important to note that some patients can develop renal disorders without progression to Multiple Myeloma.

Dive deeper into this topic and discover more about Monoclonal Gammopathies of Renal Significance in this white paper 👉 http://spr.ly/6187CSUoT

12/01/2026

Monoclonal Gammopathy of Undetermined Significance (MGUS) is often encountered by primary care providers, but what is MGUS?

Discover why this condition, a precursor to multiple myeloma, is important and why patients require monitoring. Learn more about MGUS and its significance here 👉 http://spr.ly/6187CSoit

Address

8 Calthorpe Road, Edgbaston
Birmingham
B151QT

Opening Hours

Monday 7:30am - 5pm
Tuesday 7:30am - 5pm
Wednesday 7:30am - 5pm
Thursday 7:30am - 5pm
Friday 7:30am - 5pm

Telephone

+441214569500

Website

Alerts

Be the first to know and let us send you an email when The Binding Site posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to The Binding Site:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category